中药防治化疗药草酸铂的周围神经毒性的临床观察
摘要
本论文包括文献综述和临床研究两部分。
文献综述的题目为中西医治疗草酸铂神经毒性,回顾了近年来国内外对草酸铂周围神经毒性的基础及临床研究进展,主要从临床表现、发生机制及中西医治疗进展方面进行了论述。综合分析,草酸铂致周围神经毒性是其主要的不良反应,影响患者的生活质量并可能造成停药或减量,已受到国内外诸多学者的广泛关注,通过临床观察证明,中药在预防和治疗草酸铂周围神经毒性方面有一定的疗效。
临床研究部分,观察了中药在防治化疗药草酸铂致周围神经毒性方面的疗效。目的:观察测量用草酸铂治疗胃癌、大肠癌的化疗中加用中药以减轻神经系统毒副反应的效果。方法:选择确诊为胃癌或大肠癌的患者,采用随机自身交叉对照的方法将化疗患者随机分为AB和BA两组,每例患者连续观察两个化疗周期,A周期为化疗的同时服用中药,每日早晚各一次,连续服用7天;B周期为单纯化疗。观察患者外周感觉神经毒性表现并测量了神经生长因子(NGF)。结果:共观察了73例患者,治疗组周围神经毒性的发生率为82.2%(60/73),且多为Ⅰ～Ⅱ级,少有Ⅲ级,没有Ⅳ级;对照组的发生率为87.7%(64/73),两组相比,治疗组具有明显优势(P<0.05)。共测得14例患者的血清NGF值,化疗后患者的血清NGF下降率明显低于对照组,两者具有统计学差异(P<0.05)。结论:中药对防治草酸铂化疗所引起的神经毒性反应有一定疗效,值得临床进一步研究及推广。
The paper consists of two parts: a literature review and a clinical research.
The literature review is about the advances in the treatment of peripheral neurotoxicity caused by Oxaliplatin in recent years. It includes clinical symptoms, mechanisms and the advances in management of Oxaliplatin-induced neurotoxicity with TCM and Western Medicine. Aggregate analysis, peripheral neurotoxicity caused by Oxaliplatin is its main side effect and influence the patients’quality of life. According to the clinical observation, it proved that TCM is efficient in prevention and treatment of Oxaliplatin-induced neurotoxicity.
The second part is a clinical study. Objective: To investigate the effects of TCM in the treatment of peripheral neurotoxicity caused by Oxaliplatin. Methods: All the patients were diagnosed from gastric carcinoma or colorectal carcinoma.
The patients were divided into two groups randomly. Every patients received two cycles of Oxaliplatin-based chemotherapy. The patients in treatment group received both TCM and chemotherapy. The patients in control group received chemotherapy alone. The clinical symptoms of neurotoxicity were observed, and the level of NGF before and after chemotherapy were measured. Results: 73 patients were studied. The incidence rate of peripheral neurotoxicity are 82.2% (60/73) in treatment group and 87.7% (64/73) in control group. The difference between two groups is significant (P<0.05). In 14 patients the level of NGF were measured. The descent of NGF is less serious in treatment group than that in control group after chemotherapy. Conclusion: TCM is effective in prevention and treatment peripheral neurotoxicity caused by Oxaliplatin, which is worth of a further research in oncological clinic.
文献综述的题目为中西医治疗草酸铂神经毒性,回顾了近年来国内外对草酸铂周围神经毒性的基础及临床研究进展,主要从临床表现、发生机制及中西医治疗进展方面进行了论述。综合分析,草酸铂致周围神经毒性是其主要的不良反应,影响患者的生活质量并可能造成停药或减量,已受到国内外诸多学者的广泛关注,通过临床观察证明,中药在预防和治疗草酸铂周围神经毒性方面有一定的疗效。
临床研究部分,观察了中药在防治化疗药草酸铂致周围神经毒性方面的疗效。目的:观察测量用草酸铂治疗胃癌、大肠癌的化疗中加用中药以减轻神经系统毒副反应的效果。方法:选择确诊为胃癌或大肠癌的患者,采用随机自身交叉对照的方法将化疗患者随机分为AB和BA两组,每例患者连续观察两个化疗周期,A周期为化疗的同时服用中药,每日早晚各一次,连续服用7天;B周期为单纯化疗。观察患者外周感觉神经毒性表现并测量了神经生长因子(NGF)。结果:共观察了73例患者,治疗组周围神经毒性的发生率为82.2%(60/73),且多为Ⅰ～Ⅱ级,少有Ⅲ级,没有Ⅳ级;对照组的发生率为87.7%(64/73),两组相比,治疗组具有明显优势(P<0.05)。共测得14例患者的血清NGF值,化疗后患者的血清NGF下降率明显低于对照组,两者具有统计学差异(P<0.05)。结论:中药对防治草酸铂化疗所引起的神经毒性反应有一定疗效,值得临床进一步研究及推广。
The paper consists of two parts: a literature review and a clinical research.
The literature review is about the advances in the treatment of peripheral neurotoxicity caused by Oxaliplatin in recent years. It includes clinical symptoms, mechanisms and the advances in management of Oxaliplatin-induced neurotoxicity with TCM and Western Medicine. Aggregate analysis, peripheral neurotoxicity caused by Oxaliplatin is its main side effect and influence the patients’quality of life. According to the clinical observation, it proved that TCM is efficient in prevention and treatment of Oxaliplatin-induced neurotoxicity.
The second part is a clinical study. Objective: To investigate the effects of TCM in the treatment of peripheral neurotoxicity caused by Oxaliplatin. Methods: All the patients were diagnosed from gastric carcinoma or colorectal carcinoma.
The patients were divided into two groups randomly. Every patients received two cycles of Oxaliplatin-based chemotherapy. The patients in treatment group received both TCM and chemotherapy. The patients in control group received chemotherapy alone. The clinical symptoms of neurotoxicity were observed, and the level of NGF before and after chemotherapy were measured. Results: 73 patients were studied. The incidence rate of peripheral neurotoxicity are 82.2% (60/73) in treatment group and 87.7% (64/73) in control group. The difference between two groups is significant (P<0.05). In 14 patients the level of NGF were measured. The descent of NGF is less serious in treatment group than that in control group after chemotherapy. Conclusion: TCM is effective in prevention and treatment peripheral neurotoxicity caused by Oxaliplatin, which is worth of a further research in oncological clinic.
引文
1 Fischel JL, Rostagno P, Foifmento P, et al. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines[J]. British Journal Of Cancer, 2001, 84(4): 579.
2 王少华,杜冠华.肿瘤合理用药[M].北京:人民卫生出版社,2004.239-240.
3 Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management[J]. Sem in Oncol, 2002, 29:21-33.
4 Woynarowski JM, Faivre S, Herzig MC, et al. Oxaliplatin-induced damage of cellular DNA[J]. Mol Pharmacol, 2000, 58(5): 920-927.
5 林万隆.奥沙利铂的药理作用及临床应用.中国肿瘤临床,2000,27(11):872-874.
6 Kizu R, Higashi S, Kidani Y, et al. Pharmacokinetics of (1R, 2R – diaminocyclohexane) Oxaliplatin (Ⅱ) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol, 1993, 31(6):475~480.
7 郭德嵩.第三代铂类抗癌药物奥沙利铂的研究进展.Foreign Medical Science Section on Pharmacy, 1999, 26(1): 4-8.
8 Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability[J]. J Clin Oncol, 2002, 20(7): 1767-1774.
9 Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase Ⅱ study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen[J]. Journal of Clinical Oncology, 1999, 17(11): 3560-356.
10 De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000, 18(16): 2938-2947.
11 Allain P, Heudi O, Cailleux A. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients[J]. Drug Metab Dispos, 2000, 28(11): 1379-1384.
12 Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and mdecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures[J]. Sem in Oncol, 2002, 29: 21-33.
13 Armand J P,孙燕,管忠震等.草酸铂(奥沙利铂)治疗大肠癌的研究进展[J].癌症, 1999, 18(6): 624-630.
14 Gornet JM, Savier E, Lokiec F, et al. Exacerbation of oxaliplatin neurosensory toxicity following surgery[J]. Annals of Oncol, 2002, 13: 1315-1318.
15 Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte sign and urinary relention: atypical presentation of oxaliplatin neuiotoxicity in four patients[J]. Cancer, 2002, 94: 2434-2440.
16 Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Sem in Oncol, 2002, 29: 21-33
17 Levi F,Misset JL,Brienza S,et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinc acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer[J]. Cancer,1992,69(4):893-900.
18 Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons[J]. Eur J Pharmacol, 2000, 406(1): 25-32.
19 Grolleau F, Gamelin L, Boisdron-celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels[J]. The American Physiological Society, 2001, 85(5): 2293-2297.
20 Misset J L, Brienza S, Taamma A. Pharmacokinetics, urinary and fecal excretion of oxaliplatin in cancer patients[J]. Am Ass Cancer Res Meeting abstract, 1996, 5(37): 1252-1255.
21 McKeage MJ, Hsu T, Screnci D, et al. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs[J]. British journal of Cancer, 2001, 85(8): 1219-1225.
22 马艺,王鑫等.草酸铂周围神经毒性机制研究进展[J]. 国外医学肿瘤学分册, 2005, 32(3): 234-237.
23 Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy[J]. Muscle Nerve, 2004, 29(3): 387-392.
24 Garufi C, Pietrangeli A, Brienza S, et al. Electrophysiological evaluation ofoxaliplatin neurotoxicity[J]. Proc Am Soc Clin Oncol, 1999, 18: 244.
25 Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin and axonal Na+ channel function in vivo [J]. Clinical cancer research, 2006, 12:4481-4484.
26 Cavaletti G, Petruccioli MG, Marmiroli P, et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat[J]. Anticancer Research, 2002, 22: 4199-4204.
27 Screnci D, McKeage MJ, Galettis P, et al. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs[J]. Br J Cancer, 2000, 82(4): 966-972.
28 Donzelli E, Carfi M, Miloso M, et al. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y[J]. Journal of Neuro-Oncology, 2004, 67(1-2): 65-73.
29 赵国光,何友兼.草酸铂的神经毒性及其预防和治疗,实用癌症杂志,2005, 11, 20(6): 668-672.
30 Maindrault Goebel F, Tournigand C, Andre T, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer [J]. Annals of oncology, 2004, 15: 1210-1214.
31 Alberghina M. Lipid peroxidation inhibits acyl CoA: 1- a- cyi- sn- hiyccro- 3- phosphocholinc O-acyltransfcrasc but not CTP: phosphocholine ctidylyltransferase activity in rat brain membranes[J]. Neurochem int, 1995, 26(5): 477-478.
32 Kittaka M, Ciannotta SL, Zelman V, et al. Attenuation of brain injury and reduction of neuron-specific enolase by incardipine in systemic circulation following focal ischemia and reperfusion in rat model[J]. J Nearsag, 1997,
87(5): 731-737.
33 杨渤彦,王雅茹等,三磷酸胞苷二钠防治草酸铂外周神经毒性的临床观察. Journal of Practical Oncology, 2004, 19(4):326-328.
34 Eckel F, Schmelz R, Adelsberger H, et al. Prevention of oxaliplatin-induced neuropathy by carbamazepine[J]. Deutsche Medizinische Wochenschrift, 2002, 127: 78-82.
35 Odrcich M, Bailey JM, Cahill CM, et al. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: Diurnal pain variation and effects of analgestic therapy[J]. Pain, 2006, 120(1-2): 207-212.
36 张玉芝.镁与神经系统疾病[J].微量元素与健康研究,2001,l8(4):73-74.
37 金惠铭.病理生理学[M].第 5 版.北京:人民卫生出版社,2002.44-45.
38 何敬东,岳顺等.草酸铂神经毒性的防治[J].中国肿瘤临床与康复,2004, 11(4): 324-325.
39 Gamelin L, Boisdron Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer [J]. Clinical cancer research, 2004, 15(10):4055-4061.
40 Grothey A, Oxaliplatin-safety profile: Neurotoxicity. Seminars in Oncology, 2003, 30(4 Suppl 15): 5-13.
41 Penz M, Kornek GV, Raderer M, et al. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy[J]. Annals of oncology, 2001, 12(3): 421-422.
42 林万隆,陈强.奥沙利铂的药理作用及临床应用[J].中国肿瘤临床,2000,27(11):872-874.
43 Odrcich M, Bailey JM, Cahill CM, et al. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy[J]. Pain, 2006, 120(1-2): 207-212.
44 乔虹.生长因子对化疗药物周围神经毒性的预防和治疗作用[J].国外医学药学分册, 2006,10,33(5):377-378.
45 宋晓萌.NGF 及其受体在肿瘤生长及侵袭中的作用[J].中国医学文摘, 2006, 21(3):97-100.
46 Fernyhough P, Diemel LT, Brewster WJ, et a1. Altered neurotrophin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats [J]. Journal of Neurochemistry, 1995, 64:1231-1237.
47 Zhu ZW, Friess H, Wang L, et a1. Nerve Growth Factor Exerts Differential Effects on the Growth of Human Pancreatic Cancer Cells[J]. Clin Cancer Ras, 2001, (7): 105-112
48 李君荣,唐艳林,端礼荣.NGF 对大鼠胚胎脊髓神经细胞分化和增殖作用[J].现代预防医学,2007,34(7):1282-1283.
49 王爱民,孙红振等.不同浓度的肌肉源神经生长因子对游离神经移植修复脊髓损伤的作用[J].中国临床康复,2002,6(12):381-384
50 端礼荣,吴全义,张志坚等.神经生长因子对大鼠胚胎脊髓神经细胞的作用[J].中国临床康复,2004,8 (11):265-267.
51 Missale C, Codignola A, Sigala S, et al. Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines[J].Proceedings of the National Academy of Sciences of the United States of Americ.1998,95(9): 5366-5371.
52 Sigala S, Tognazzi N, Rizzetti MC, et al. Nerve growth factor induces the re-expression of functional androgen receptors and p75 in the androgen insensitive prostate cancer cell line DU145[J]. European journal of endocrinology, 2002, 147(3): 407-415.
53 Apfel, SC. Neurotrophic factors in peripheral neuropathies: therapeutic implications[J]. Brain pathology, 1999, 9(2): 393-413.
54 Svensson P, Cairns BE, Wang K, et al. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia[J]. Pain, 2003, 104(1-2): 241-247.
55 Chauhan NB, Siegel GJ. Effect of PPF and ALCAR on the induction of NGF and p75 mRNA and on APP processing in Tg2576 brain[J]. Neurochemistry International, 2003, 43:225-233.
56 Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and Cisplatin induced neurotoxicity: a protective role of acetyl-L-camitine[J]. Clin Cancer Res, 2003, 9:5756-5767.
57 De Santis S, Pace A, Bove L, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor [J]. Clinical cancer research, 2000, 6(1):90-95.
58 李倩,郭伟剑,陈强等.奥沙利铂化疗中血清NGF的动态变化及意义[J].肿瘤,2007,6,27(6):454-458.
59 冯兴华.论痹证病因非独外感风寒湿热[J].北京中医,2007,1,26(1):30-31.
60 柴可夫.《金匮要略》论痹病的病因病机探讨[J].中医函授通讯, 1999, 18(2): 6-7.
61 吴敦序.中医基础理论[M].上海科学技术出版社,1999.45-46.
62 梁波. 黄芪桂枝五物汤临床运用. 实用中医内科杂[J]志, 2006, 20(2): 170-171.
63 马丽. 黄茂桂枝五物汤对糖尿病周围神经病变微循环障碍的影响[J]. 辽宁中医杂志, 2006,33(2):140-141.
64 董雪, 张梅. 加味黄芪桂枝五物汤防治草酸铂所致神经毒性观察[J].中医药临床杂志,2006,18(6):563-564.
65 张若燕, 李利亚,吊清临.加味黄芪桂枝五物汤防治希罗达相关性手足综合征的临床观察[J].辽宁中医杂志,2007,34(6):783-784.
66 戴虹,潘宇,王晓露.补阳还五汤加味治疗草酸铂化疗后周围神经毒性 42 例[J].实用中医内科杂志,2006,10(5):518-519.
67 李安国.补阳还五汤对血管壁抗血栓功能的影响[J].中西医结台杂志.1989,(9):545-547.
68 胡奇芬.补阳还五汤注射剂药效机理研究[J].老年学杂志,1990,2:87.
69 张汀荣,许晨,沈伟生等.参附注射液联合肉桂防治奥沙利铂神经毒性疗效观察[J].中国药房,2006,17,20:1570-1571.
70 雷静,李琼,田丽华等.参附注射液减轻肿瘤化疗毒性反应及改善生活质量的作用[J].中国中医急症,2004,13(12):813.
71 韩俊生.肉桂“引火归源”之我见[J].上海中医药杂志,2004,38(8):47.
72 黄敬群,王四汪.桂皮醛药理研究进展[J].中国新医药,2004,3(9):61.
1 王少华,杜冠华.肿瘤合理用药[M].北京:人民卫生出版社, 2004.239 240.
2 Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management[J]. Sem in Oncol, 2002, 29:21-33.
3 李洁,金懋林,杨伯秦等.乐沙定联合氟尿嘧啶、甲酰四氢叶酸治疗进展期大肠癌21例分析[J].中国肿瘤临床,2001,28(4):265-266.
4 Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability[J]: Clin Oncol, 2002, 20(7): 1767-1774.
5 M isset JL. Oxaliplatin in practice[J]. Br J Cancer, 1998,,77(14): 4.
6 Extra JM, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin[J]. Semin Oncol, 1998, 25: 13.
7 Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and mdecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures[J]. Sem in Oncol, 2002, 29: 21-33.
8 Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinc acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer[J]. Cancer, 1992,69(4):893-900.
9 De Santis S, Pace A, Bove L, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor [J]. Clinical cancer research,2000,6(1):90-95.
10 Fischel JL, Rostagno P, Foifmento P, et al. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines[J]: British Journal of Cancer, 2001, 84(4):579.
11 苏庆光,车成云.草酸铂的临床研究进展.国外医学肿瘤学分册[M].1999;26 (4):208-210.
12 Raymond E, Chaney G, Taama A, et al.Oxaliplatin:A review of precIinical and Clinical studies [J]. Ann Oncol 1998; 9(10):1053-1071.
13 胡国清,付强,金懋林等.草酸铂联合羟基喜树碱、氟脲嘧啶、甲酰四氢叶酸钙治疗晚期胃癌 36 例的临床观察[J].中国肿瘤临床 2004;3(19):506-512.
14 Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase Ⅱ study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen[J]. Journal of Clinical Oncology, 1999, 17(11): 3560-3568.
15 De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000, 18(16): 2938-2947.
16 赵国光,何友兼.草酸铂的神经毒性及其预防和治疗[J].实用癌症杂志,2005, 11,20(6):668-672.
17 Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol, 2000, 406(1):25-32.
18 Grolleau F, Gamelin L, Boisdron-celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels[J]. The American Physiological Society, 2001, 85(5):2293–2297.
19 Cavaletti G, Pezzoni G, Pisano C,et al. Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor [J]. Neuroscience Letters, 2002,322(2):103-106.
20 李倩,郭伟剑,陈强等.奥沙利铂化疗中血清NGF的动态变化及意义[J].肿瘤,2007,6,27(6):454-458.
2 王少华,杜冠华.肿瘤合理用药[M].北京:人民卫生出版社,2004.239-240.
3 Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management[J]. Sem in Oncol, 2002, 29:21-33.
4 Woynarowski JM, Faivre S, Herzig MC, et al. Oxaliplatin-induced damage of cellular DNA[J]. Mol Pharmacol, 2000, 58(5): 920-927.
5 林万隆.奥沙利铂的药理作用及临床应用.中国肿瘤临床,2000,27(11):872-874.
6 Kizu R, Higashi S, Kidani Y, et al. Pharmacokinetics of (1R, 2R – diaminocyclohexane) Oxaliplatin (Ⅱ) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol, 1993, 31(6):475~480.
7 郭德嵩.第三代铂类抗癌药物奥沙利铂的研究进展.Foreign Medical Science Section on Pharmacy, 1999, 26(1): 4-8.
8 Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability[J]. J Clin Oncol, 2002, 20(7): 1767-1774.
9 Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase Ⅱ study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen[J]. Journal of Clinical Oncology, 1999, 17(11): 3560-356.
10 De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000, 18(16): 2938-2947.
11 Allain P, Heudi O, Cailleux A. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients[J]. Drug Metab Dispos, 2000, 28(11): 1379-1384.
12 Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and mdecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures[J]. Sem in Oncol, 2002, 29: 21-33.
13 Armand J P,孙燕,管忠震等.草酸铂(奥沙利铂)治疗大肠癌的研究进展[J].癌症, 1999, 18(6): 624-630.
14 Gornet JM, Savier E, Lokiec F, et al. Exacerbation of oxaliplatin neurosensory toxicity following surgery[J]. Annals of Oncol, 2002, 13: 1315-1318.
15 Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte sign and urinary relention: atypical presentation of oxaliplatin neuiotoxicity in four patients[J]. Cancer, 2002, 94: 2434-2440.
16 Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Sem in Oncol, 2002, 29: 21-33
17 Levi F,Misset JL,Brienza S,et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinc acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer[J]. Cancer,1992,69(4):893-900.
18 Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons[J]. Eur J Pharmacol, 2000, 406(1): 25-32.
19 Grolleau F, Gamelin L, Boisdron-celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels[J]. The American Physiological Society, 2001, 85(5): 2293-2297.
20 Misset J L, Brienza S, Taamma A. Pharmacokinetics, urinary and fecal excretion of oxaliplatin in cancer patients[J]. Am Ass Cancer Res Meeting abstract, 1996, 5(37): 1252-1255.
21 McKeage MJ, Hsu T, Screnci D, et al. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs[J]. British journal of Cancer, 2001, 85(8): 1219-1225.
22 马艺,王鑫等.草酸铂周围神经毒性机制研究进展[J]. 国外医学肿瘤学分册, 2005, 32(3): 234-237.
23 Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy[J]. Muscle Nerve, 2004, 29(3): 387-392.
24 Garufi C, Pietrangeli A, Brienza S, et al. Electrophysiological evaluation ofoxaliplatin neurotoxicity[J]. Proc Am Soc Clin Oncol, 1999, 18: 244.
25 Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin and axonal Na+ channel function in vivo [J]. Clinical cancer research, 2006, 12:4481-4484.
26 Cavaletti G, Petruccioli MG, Marmiroli P, et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat[J]. Anticancer Research, 2002, 22: 4199-4204.
27 Screnci D, McKeage MJ, Galettis P, et al. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs[J]. Br J Cancer, 2000, 82(4): 966-972.
28 Donzelli E, Carfi M, Miloso M, et al. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y[J]. Journal of Neuro-Oncology, 2004, 67(1-2): 65-73.
29 赵国光,何友兼.草酸铂的神经毒性及其预防和治疗,实用癌症杂志,2005, 11, 20(6): 668-672.
30 Maindrault Goebel F, Tournigand C, Andre T, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer [J]. Annals of oncology, 2004, 15: 1210-1214.
31 Alberghina M. Lipid peroxidation inhibits acyl CoA: 1- a- cyi- sn- hiyccro- 3- phosphocholinc O-acyltransfcrasc but not CTP: phosphocholine ctidylyltransferase activity in rat brain membranes[J]. Neurochem int, 1995, 26(5): 477-478.
32 Kittaka M, Ciannotta SL, Zelman V, et al. Attenuation of brain injury and reduction of neuron-specific enolase by incardipine in systemic circulation following focal ischemia and reperfusion in rat model[J]. J Nearsag, 1997,
87(5): 731-737.
33 杨渤彦,王雅茹等,三磷酸胞苷二钠防治草酸铂外周神经毒性的临床观察. Journal of Practical Oncology, 2004, 19(4):326-328.
34 Eckel F, Schmelz R, Adelsberger H, et al. Prevention of oxaliplatin-induced neuropathy by carbamazepine[J]. Deutsche Medizinische Wochenschrift, 2002, 127: 78-82.
35 Odrcich M, Bailey JM, Cahill CM, et al. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: Diurnal pain variation and effects of analgestic therapy[J]. Pain, 2006, 120(1-2): 207-212.
36 张玉芝.镁与神经系统疾病[J].微量元素与健康研究,2001,l8(4):73-74.
37 金惠铭.病理生理学[M].第 5 版.北京:人民卫生出版社,2002.44-45.
38 何敬东,岳顺等.草酸铂神经毒性的防治[J].中国肿瘤临床与康复,2004, 11(4): 324-325.
39 Gamelin L, Boisdron Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer [J]. Clinical cancer research, 2004, 15(10):4055-4061.
40 Grothey A, Oxaliplatin-safety profile: Neurotoxicity. Seminars in Oncology, 2003, 30(4 Suppl 15): 5-13.
41 Penz M, Kornek GV, Raderer M, et al. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy[J]. Annals of oncology, 2001, 12(3): 421-422.
42 林万隆,陈强.奥沙利铂的药理作用及临床应用[J].中国肿瘤临床,2000,27(11):872-874.
43 Odrcich M, Bailey JM, Cahill CM, et al. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy[J]. Pain, 2006, 120(1-2): 207-212.
44 乔虹.生长因子对化疗药物周围神经毒性的预防和治疗作用[J].国外医学药学分册, 2006,10,33(5):377-378.
45 宋晓萌.NGF 及其受体在肿瘤生长及侵袭中的作用[J].中国医学文摘, 2006, 21(3):97-100.
46 Fernyhough P, Diemel LT, Brewster WJ, et a1. Altered neurotrophin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats [J]. Journal of Neurochemistry, 1995, 64:1231-1237.
47 Zhu ZW, Friess H, Wang L, et a1. Nerve Growth Factor Exerts Differential Effects on the Growth of Human Pancreatic Cancer Cells[J]. Clin Cancer Ras, 2001, (7): 105-112
48 李君荣,唐艳林,端礼荣.NGF 对大鼠胚胎脊髓神经细胞分化和增殖作用[J].现代预防医学,2007,34(7):1282-1283.
49 王爱民,孙红振等.不同浓度的肌肉源神经生长因子对游离神经移植修复脊髓损伤的作用[J].中国临床康复,2002,6(12):381-384
50 端礼荣,吴全义,张志坚等.神经生长因子对大鼠胚胎脊髓神经细胞的作用[J].中国临床康复,2004,8 (11):265-267.
51 Missale C, Codignola A, Sigala S, et al. Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines[J].Proceedings of the National Academy of Sciences of the United States of Americ.1998,95(9): 5366-5371.
52 Sigala S, Tognazzi N, Rizzetti MC, et al. Nerve growth factor induces the re-expression of functional androgen receptors and p75 in the androgen insensitive prostate cancer cell line DU145[J]. European journal of endocrinology, 2002, 147(3): 407-415.
53 Apfel, SC. Neurotrophic factors in peripheral neuropathies: therapeutic implications[J]. Brain pathology, 1999, 9(2): 393-413.
54 Svensson P, Cairns BE, Wang K, et al. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia[J]. Pain, 2003, 104(1-2): 241-247.
55 Chauhan NB, Siegel GJ. Effect of PPF and ALCAR on the induction of NGF and p75 mRNA and on APP processing in Tg2576 brain[J]. Neurochemistry International, 2003, 43:225-233.
56 Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and Cisplatin induced neurotoxicity: a protective role of acetyl-L-camitine[J]. Clin Cancer Res, 2003, 9:5756-5767.
57 De Santis S, Pace A, Bove L, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor [J]. Clinical cancer research, 2000, 6(1):90-95.
58 李倩,郭伟剑,陈强等.奥沙利铂化疗中血清NGF的动态变化及意义[J].肿瘤,2007,6,27(6):454-458.
59 冯兴华.论痹证病因非独外感风寒湿热[J].北京中医,2007,1,26(1):30-31.
60 柴可夫.《金匮要略》论痹病的病因病机探讨[J].中医函授通讯, 1999, 18(2): 6-7.
61 吴敦序.中医基础理论[M].上海科学技术出版社,1999.45-46.
62 梁波. 黄芪桂枝五物汤临床运用. 实用中医内科杂[J]志, 2006, 20(2): 170-171.
63 马丽. 黄茂桂枝五物汤对糖尿病周围神经病变微循环障碍的影响[J]. 辽宁中医杂志, 2006,33(2):140-141.
64 董雪, 张梅. 加味黄芪桂枝五物汤防治草酸铂所致神经毒性观察[J].中医药临床杂志,2006,18(6):563-564.
65 张若燕, 李利亚,吊清临.加味黄芪桂枝五物汤防治希罗达相关性手足综合征的临床观察[J].辽宁中医杂志,2007,34(6):783-784.
66 戴虹,潘宇,王晓露.补阳还五汤加味治疗草酸铂化疗后周围神经毒性 42 例[J].实用中医内科杂志,2006,10(5):518-519.
67 李安国.补阳还五汤对血管壁抗血栓功能的影响[J].中西医结台杂志.1989,(9):545-547.
68 胡奇芬.补阳还五汤注射剂药效机理研究[J].老年学杂志,1990,2:87.
69 张汀荣,许晨,沈伟生等.参附注射液联合肉桂防治奥沙利铂神经毒性疗效观察[J].中国药房,2006,17,20:1570-1571.
70 雷静,李琼,田丽华等.参附注射液减轻肿瘤化疗毒性反应及改善生活质量的作用[J].中国中医急症,2004,13(12):813.
71 韩俊生.肉桂“引火归源”之我见[J].上海中医药杂志,2004,38(8):47.
72 黄敬群,王四汪.桂皮醛药理研究进展[J].中国新医药,2004,3(9):61.
1 王少华,杜冠华.肿瘤合理用药[M].北京:人民卫生出版社, 2004.239 240.
2 Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management[J]. Sem in Oncol, 2002, 29:21-33.
3 李洁,金懋林,杨伯秦等.乐沙定联合氟尿嘧啶、甲酰四氢叶酸治疗进展期大肠癌21例分析[J].中国肿瘤临床,2001,28(4):265-266.
4 Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability[J]: Clin Oncol, 2002, 20(7): 1767-1774.
5 M isset JL. Oxaliplatin in practice[J]. Br J Cancer, 1998,,77(14): 4.
6 Extra JM, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin[J]. Semin Oncol, 1998, 25: 13.
7 Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and mdecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures[J]. Sem in Oncol, 2002, 29: 21-33.
8 Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinc acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer[J]. Cancer, 1992,69(4):893-900.
9 De Santis S, Pace A, Bove L, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor [J]. Clinical cancer research,2000,6(1):90-95.
10 Fischel JL, Rostagno P, Foifmento P, et al. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines[J]: British Journal of Cancer, 2001, 84(4):579.
11 苏庆光,车成云.草酸铂的临床研究进展.国外医学肿瘤学分册[M].1999;26 (4):208-210.
12 Raymond E, Chaney G, Taama A, et al.Oxaliplatin:A review of precIinical and Clinical studies [J]. Ann Oncol 1998; 9(10):1053-1071.
13 胡国清,付强,金懋林等.草酸铂联合羟基喜树碱、氟脲嘧啶、甲酰四氢叶酸钙治疗晚期胃癌 36 例的临床观察[J].中国肿瘤临床 2004;3(19):506-512.
14 Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase Ⅱ study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen[J]. Journal of Clinical Oncology, 1999, 17(11): 3560-3568.
15 De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000, 18(16): 2938-2947.
16 赵国光,何友兼.草酸铂的神经毒性及其预防和治疗[J].实用癌症杂志,2005, 11,20(6):668-672.
17 Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol, 2000, 406(1):25-32.
18 Grolleau F, Gamelin L, Boisdron-celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels[J]. The American Physiological Society, 2001, 85(5):2293–2297.
19 Cavaletti G, Pezzoni G, Pisano C,et al. Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor [J]. Neuroscience Letters, 2002,322(2):103-106.
20 李倩,郭伟剑,陈强等.奥沙利铂化疗中血清NGF的动态变化及意义[J].肿瘤,2007,6,27(6):454-458.